Funding News Healthcare

RISA Labs Secures $11.1M in Series A Funding Backed by Binny Bansal to Transform Oncology Workflows

• ByStartupStory     |    January 14, 2026

In a definitive move to eliminate administrative bottlenecks in cancer care, RISA Labs, an AI-driven healthcare startup, has successfully closed an $11.1 million Series A funding round. Announced on January 13, 2026, the investment highlights the growing demand for specialized AI operating systems in mission-critical medical environments.

The round was co-led by Cencora Ventures and Optum Ventures, with significant participation from Binny Bansal (Flipkart co-founder and existing backer), Oncology Ventures, Z21 Ventures, and John Simon (co-founder of General Catalyst) via his Ventureforgood entity.

BOSS: The AI Operating System for Oncology

At the heart of RISA Labs is its flagship platform, BOSS (Business Operating System as a Service). Founded by IIT Kanpur alumni Kshitij Jaggi (CEO) and Kumar Shivang (CTO), the platform is designed to tackle one of the most dangerous hurdles in healthcare: Prior Authorization delays.

In oncology, 70% of patients face treatment delays due to insurance paperwork—a lag that can increase mortality risks. RISA Labs solves this by deploying a “digital workforce” of AI agents that:

• Integrate Directly: Connects with Electronic Medical Records (EMRs) and insurance benefit systems.

• Automate Complexity: Uses LLMs and digital twins to break down complex medical workflows into micro-tasks.

• Adapt in Real-Time: Unlike traditional bots, RISA’s agents adapt to changing insurance rules and forms without needing constant reprogramming.

“In our vision for oncology, there are two sides to every patient’s journey: getting them on the right therapy faster, and deepening our understanding of the disease for the next patient through data.” > — Kshitij Jaggi, CEO of RISA Labs.

Proven Impact & Strategic Scaling

The $11.1 million capital injection follows a successful seed round of $3.5 million led by Binny Bansal in 2025. The fresh funds are earmarked for an aggressive nationwide rollout across:

• Cancer Clinics & Health Systems

• Specialty Pharmacies

• Infusion Networks

Operational Success Metrics to Date:

• Efficiency: Reduced prior authorization times from an average of 8 days to under 24 hours.

• Staff Recovery: Freed up approximately 80% of administrative staff time, allowing teams to focus on patient care.

• Financial Performance: Reduced insurance denials by up to 40% and achieved a 97.8% first-pass approval rate.

The Road Ahead: 2026 and Beyond

With the support of Cencora and Optum, RISA Labs is moving toward becoming the “orchestration layer” for the entire cancer care continuum. The company plans to expand its AI-driven workflows into specialty pharmacy operations later this year, ensuring that as cancer treatments become more complex, the administrative pathways to receive them become simpler and faster.

As Binny Bansal noted during the funding announcement, RISA’s BOSS is leading the way in “unbundling the services industry” by proving that AI can handle the most vertically complex challenges in healthcare.

Follow Startup Story